2013 55th ASH Annual Meeting - účast ČR

101. Red Cells and Erythropoiesis, Structure and Function, Metabolism and Survival, Excluding Iron: Poster II

102. Regulation of Iron Metabolism: Poster I

102. Regulation of Iron Metabolism: Poster II

112. Thalassemia and Globin Gene Regulation: Poster III

311. Disorders of Platelet Number or Function: Poster II

322. Disorders of Coagulation or Fibrinolysis: Inhibitors in Hemophilia A

322. Disorders of Coagulation or Fibrinolysis: Poster III

508. Bone Marrow Failure: Poster II

601. Chromosomal Rearrangements and DNA Repair

602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Poster II

602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Poster III

603. Oncogenes and Tumor Suppressors: Poster III

604. Molecular Pharmacology, Drug Resistance: Poster III

611. Leukemias: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis I

611. Leukemias: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Poster I

611. Leukemias: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Poster II

615. Acute Myeloid Leukemia: Therapy, excluding Transplantation: Poster II

621. Hodgkin Lymphoma: Biology, excluding Therapy: Genomics

Autoři: D.O. Wendy Cozen, M.P.H.; M.D. Dalin Li, Ph.D.; Maria Timofeeva, Ph.D.; M.D. Arjan Diepstra, Ph.D.; Denis Hazelett, Ph.D.; Manon Delahaye-Sourdeix, M.S.; Christopher K. Edlund, M.S.; Klaus Rostgaard, Ph.D.; David J. van den Berg; Lude Franke, Ph.D.; M.D. Karin Ekström Smedby, Ph.D.; Sally L. Glaser, Ph.D.; Harm-Jam Westra, Ph.D.; Leslie L. Robinson, Ph.D.; Prof. M.D. Thomas M. Mack, M.P.H.; M.D. Herve Ghesquieres, Ph.D.; Amie E. Hwang, Ph.D., M.P.H.; Alexandra Nieters, Ph.D., M.P.H.; M.D. Silvia de Sanjosé, Ph.D.; Victoria K. Cortessis, Ph.D.; Dr. Tracy Lightfoot; M.D. Nikolaus Becker, Ph.D.; M.D. Marc Maynadie, Ph.D.; Doc.MUDr. Lenka Foretová , Ph.D.; Prof. M.D. Eve Roman; Yolanda Benavente, Ph.D.; Dr. Bharat N. Nathwani; M.D. Bengt Glimelius, Ph.D.; Prof. MUDr. Anthony Staines, Ph.D.; M.D. Paolo Boffetta, M.P.H.; M.D. Brian K. Link; Lambertus A. Kiemeney, Ph.D.; M.D. Stephen M. Ansell, Ph.D.; M.D. Smita Bhatia, Ph.D.; Dr. Louise C. Strong, Ph.D.; M.D. Pilar Galan; M.D. Lars Vatten, Ph.D.; M.D. Thomas M. Habermann; Eric J. Duell, Ph.D., M.S.; Annette Lake, M.S.; Rianne Veenstra; M.D. Lydia Visser, Ph.D.; Kevin Urayama, Ph.D.; Dorothy Montgomery; Valerie Gaborieau; M.D. Lawrence Weiss; Dr. Graham Byrnes; Dr. Marc Lathrop, Ph.D.; Prof. M.D. Hans-Olov Adami, Ph.D.; Prof. M.D. Mads Melbye, DMSc; M.D. James R. Cerhan, Ph.D.; M.D. Alice Gallagher; M.D. J. Malcom Taylor; M.D. Susan L. Slager, Ph.D.; M.D. Paul Brennan, Ph.D.; David V. Conti, Ph.D.; Prof. M.D. Gerhard Coetzee, Ph.D.; M.D. Kenan Onel, Ph.D.; Prof. M.D. Ruth F. Jarrett, Ph.D.; M.D. Henrik Hjalgrim, Ph.D.; M.D. Anke Van Den Berg, Ph.D.; M.D. James D. McKay, Ph.D.
Číslo abstraktu: 626
Kategorie: Maligní lymfomy a leukémie

622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Poster I

622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Poster II

622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Poster III

623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Poster III

624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster III

624. Lymphoma: Therapy with Biological Agents, Excluding Pre-Clinical Models: Aggressive Lymphomas

624. Lymphoma: Therapy with Biological Agents, Excluding Pre-Clinical Models: Immunotherapy for Indolent Lymphomas

625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Small Molecule Targets in Lymphoma

631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster III

632. Chronic Myeloid Leukemia: Therapy: Emerging Aspects of Monitoring and Long-Term Treatment

632. Chronic Myeloid Leukemia: Therapy: Poster I

632. Chronic Myeloid Leukemia: Therapy: Poster II

632. Chronic Myeloid Leukemia: Therapy: Poster III

632. Chronic Myeloid Leukemia: Therapy: Prognosis

633. Myelodysplastic Syndromes: Poster I

633. Myelodysplastic Syndromes: Poster II

635. Myeloproliferative Syndromes: Basic Science: Poster I

641. CLL: Biology and Pathophysiology, excluding Therapy: Poster I

641. CLL: Biology and Pathophysiology, excluding Therapy: Poster II

641. CLL: Biology and Pathophysiology, excluding Therapy: Poster III

642. CLL: Therapy, excluding Transplantation: Chemoimmunotherapy Clinical Trials

642. CLL: Therapy, excluding Transplantation: Poster II

642. CLL: Therapy, excluding Transplantation: Poster III

651. Myeloma: Biology and Pathophysiology, excluding Therapy: Microenvironment

651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I

653. Myeloma: Therapy, excluding Transplantation: Poster II

653. Myeloma: Therapy, excluding Transplantation: Treatment Options for Newly Diagnosed Multiple Myeloma Patients

722. Clinical Allogeneic Transplantation - Acute and Chronic GVHD, Immune Reconstitution: Poster III

731. Clinical Allogeneic and Autologous Transplantation - Results: Allogeneic Transplantation

731. Clinical Allogeneic and Autologous Transplantation - Results: Evidence-based Decision Making II - Transplantation for Lymphoma and Plasma Cell Disorders

731. Clinical Allogeneic and Autologous Transplantation - Results: Poster I

901. Health Services and Outcomes Research: Poster I